March 18, 2020
ASF Funded Research leads to a collaboration for gene therapy to correct deficiency in UBE3A gene Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy company, entered into a research collaboration and licensing agreement with the […]
Read more
March 13, 2020
Coronavirus Disease 2019 (COVID-19) Questions and Answers (FAQs) Due to quickly evolving information, recommendations may be subject to change and will be updated as needed. The 15q Clinical Research Network has prepared these FAQs to address concerns from the Angelman/Dup15q […]
Read more
November 25, 2019
A new network platform, Linking Angelman and Dup15q Data for Expanded Research (LADDER), will offer caregivers access to information about a larger population of patients living with Angelman or Dup15 syndromes to better inform their decisions regarding treatments and interventions. […]
Read more
November 18, 2019
Angelman Syndrome Foundation and Dup15q Alliance Announce Development of the International Clinical Research Network in efforts to help those living with 15q syndromes. Thousands of families affected by Angelman syndrome (AS) and dup15q syndrome will soon have greater access to […]
Read more
September 18, 2019
A UNC Healthcare announced on September 17, 2019: The National Institutes of Health have awarded two separate grants totaling $6.1 million to Mark Zylka, PhD, director of the UNC Neuroscience Center.at the UNC School of Medicine. One of these projects […]
Read more
September 16, 2019
An ASF funded research study was published in BioRXiv and the Journal of Clinical Investigation. See the press release below for more information and the outcomes of the study. UNC School of Medicine researchers led by Ben Philpot, PhD, and Bin Gu, PhD, found that […]
Read more
August 19, 2019
Neuren Pharmaceutical’s candidate NNZ-2591 has shown positive effects in a mouse model of Angelman syndrome, treating all symptoms of the disease, the company announced. These results were used to submit an Orphan Drug application to the U.S. Food and Drug Administration (FDA). Angelman syndrome is a genetic neurological […]
Read more
August 4, 2019
At the 2019 ASF Scientific Symposium and Family Conference in Louisville, KY, the Angelman Syndrome Foundation recognized four people with special awards at the Family Conference Welcome Reception. The board and staff of the Angelman Syndrome Foundation, as well as […]
Read more